alectinib相关论文
目的 Basedonitshighefficacyandgoodtolerance,alectinib,asecondgenerationselectiveanaplasticlymphomakinase(ALK)inhibitor,m......
Objective: The central nervous system (CNS) is a frequent site of progression in ALK+ NSCLC patients treated with crizot......
1 文献来源rnPeters S, Camidge DR, Shaw AT, et al.Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lu......
目的:本研究旨在探讨采用胰岛素生长因子-1（IGF-1）诱导棘皮动物微管相关蛋白样4与间变性淋巴瘤激酶（echinoderm microtubule-associat......
Alectinib是一种口服间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)抑制剂,能选择性抑制ALK和转染重排(rearranged during tr......
,Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clin
...
目的:探讨阿来替尼治疗ALK融合重排非小细胞肺癌(non-small cell lung cance,NSCLC)脑转移患者的疗效及不良反应。方法:回顾性分析......
艾乐替尼是一种新型抗癌药,2-(3-碘-4-乙基苯基)-2-甲基丙酸作为其重要的中间体,在合成新药中有着重要的研究价值,广阔的市场和良......
克唑替尼作为第一代间变性淋巴瘤激酶酪氨酸激酶抑制剂(anaplastic lymphoma kinase-tyrosine kinase inhibitors,ALKTKIs),在间变......
的 观察mTOR信号通路在17-DMAG克服旁路信号通路激活诱导棘皮动物微管相关蛋白样4与间变性淋巴瘤激酶（echinoderm microtubule-asso......
1文献来源Peters S,Camidge DR,Shaw AT,et al.Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung can......
Central nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC/ALK t
BACKGROUND The aberrant expression of the anaplastic lymphoma kinase(ALK)gene in ALKpositive(ALK+)anaplastic large cell ......
目的:间变性淋巴瘤激酶酪氨酸激酶抑制剂(anaplastic lymphoma kinase tyrosine kinase inhibitor,ALK-TKI)的耐药已成为其临床应......
目的:观察mTOR信号通路在17-DMAG克服旁路信号通路激活诱导棘皮动物微管相关蛋白样4与间变性淋巴瘤激酶(echinoderm microtubule-a......
目的：本研究旨在探讨肝细胞生长因子（HGF）、表皮生长因子（EGF）及转化生长因子α（TGF-α）是否以旁路激活的方式诱导EML4-ALK融合基因阳性肺......
